Directa Plus Valuation
Is 88K undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 88K when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 88K's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 88K's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 88K?
Key metric: As 88K is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 88K's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | €9.33m |
| Market Cap | €10.95m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | -3.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 88K's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BIG1 Bio-Gate | 0.8x | 16.3% | €6.3m |
BNN BRAIN Biotech | 1.3x | 8.5% | €70.8m |
NTG Nabaltec | 0.6x | 5.1% | €122.3m |
2HRA H&R GmbH KGaA | 0.1x | 3.0% | €128.4m |
88K Directa Plus | 1.2x | 43.5% | €9.1m |
Price-To-Sales vs Peers: 88K is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 88K's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: 88K is expensive based on its Price-To-Sales Ratio (1.2x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 88K's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 2.8x |
Price-To-Sales vs Fair Ratio: 88K is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Compañía de Minas BuenaventuraA
US$3.1b
Engages in the exploration, development, construction, and operation of mineral processing business.
MBU
US$11.70
7D
0.9%
1Y
41.8%
Ecora Resources
UK£162.5m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
HGR
UK£0.76
7D
-1.4%
1Y
-29.4%
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.55
7D
-5.4%
1Y
-19.6%